

## CLAIMS

1. Use of an Interleukin 1 receptor antagonist (IL-1Ra) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal.
2. The use according to claim 1, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant protein (rIL-1Ra).  
5
3. The use according to any of the preceding claims, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra).
4. The use according to any of the preceding claims, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).
- 10 5. The use according to any of the preceding claims, wherein the medicament is adapted for parenteral administration.
6. Use of pyrrolidinedithiocarbamate (PDTC) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal.
7. The use according to claim 6, wherein the medicament is adapted for parenteral  
15 administration.
8. A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of an Interleukin 1 receptor antagonist (IL-1Ra).
9. The method according to claim 8, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant protein (rIL-1Ra).  
20
10. The method according to 9, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra).
11. The method according to claim 8, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).
- 25 12. The method according to claim 8, wherein the medicament is adapted for parenteral

administration.

13. A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of pyrrolidinedithiocarbamate (PDTC).

- 5 14. The method according to claim 13, wherein the medicament is adapted for parenteral administration.